TABLE 2.
ADAMTS13 activity and VWF Ag plasma concentration. ADAMTS13 activity and VWF Ag plasma concentration in survivors and nonsurvivors. ADAMTS13 activity and VWF Ag plasma concentration in nonsurvivors and severe disease survivors
| Parameter | Whole sample (100) | Nonsevere COVID‐19 (50) | Severe COVID‐19 (50) |
Significance P (nonsevere vs severe) |
|---|---|---|---|---|
| ADAMTS13, median (IQR) |
61% (47.2‐74.6) |
69% (54.2‐84.9) |
53.2% (38.8‐65.3) |
<.0001 |
| VWF‐Ag, median (IQR) |
289% (228‐382) |
261.4% (213‐326) |
355% (267‐400) |
<.0001 |
| Parameter |
Survivors (81) |
Nonsurvivors (19) |
Significance P |
|
|---|---|---|---|---|
| ADAMTS13, median (IQR) |
62.8% (52.3‐80.1) |
42.4% (33.8‐57.3) |
<.0001 | |
| VWF‐Ag, median (IQR) |
270% (218‐353) |
395% (294‐400) |
.002 |
| Parameter | Severe disease survivors (31) | Nonsurvivors (19) |
Significance P |
|
|---|---|---|---|---|
| ADAMTS13, median (IQR) |
59.1% (46.2‐69.8) |
42.4% (33.8‐57.3) |
.016 | |
| VWF‐Ag, median (IQR) |
315% (236‐400) |
395% (294‐400) |
.18 |
Abbreviations: ADAMTS13, A disintegrin‐like and metalloprotease with thrombospondin type 1 motif no. 13; IQR, interquartile range; VWF Ag, von Willebrand factor antigen.